14 Analysts Assess Vertex Pharmaceuticals: What You Need To Know
Portfolio Pulse from Benzinga Insights
Vertex Pharmaceuticals (NASDAQ:VRTX) has been analyzed by 14 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is $474.86, with a high of $555.00 and a low of $376.00. Recent analyst actions include several rating raises and price target increases, reflecting positive sentiment towards the company's financial performance and product portfolio.
July 31, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals has received mixed analyst ratings over the past three months, with a recent trend towards positive sentiment. The average 12-month price target is $474.86, up 6.67% from the previous average. Recent analyst actions include several rating raises and price target increases, indicating confidence in the company's financial performance and product portfolio.
The majority of recent analyst actions have been positive, with several rating raises and price target increases. This suggests a bullish outlook on Vertex Pharmaceuticals' stock in the short term. The company's strong financial performance and diversified product portfolio further support this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100